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Abstract
Introduction Endocrine therapy is the most important treatment
option for women with hormone-receptor-positive breast
cancer. The potential mechanisms for endocrine resistance
involve estrogen receptor (ER)-coregulatory proteins and
crosstalk between ER and other growth factor signaling
networks. However, the factors and pathways responsible for
endocrine resistance are still poorly identified.
Methods Using immunohistochemical techniques, we focused
on the expression and phosphorylation of hormone receptors
themselves and examined the phosphorylation of ER-α  Ser118
and ER-α  Ser167 and the expression of ER-α , ER-β 1, ER-β cx/
β 2, progesterone receptor (PR), PRA, and PRB in the primary
breast carcinomas of 75 patients with metastatic breast cancer
who received first-line treatment with endocrine therapy after
relapse.
Results Phosphorylation of ER-α  Ser118, but not Ser167, was
positively associated with overexpression of HER2, and HER2-
positive tumors showed resistance to endocrine therapy. The
present study has shown for the first time that phosphorylation
of ER-α  Ser167, but not Ser118, and expression of PRA and
PRB, as well as ER-α  and PR in primary breast tumors are
predictive of response to endocrine therapy, whereas
expression of ER-β 1 and ER-β cx/β 2 did not affect response to
the therapy. In addition, patients with either high
phosphorylation of ER-α  Ser167, or high expression of ER-α ,
PR, PRA, or PRB had a significantly longer survival after relapse.
Conclusion These data suggest that phosphorylation of ER-α
Ser167 is helpful in selecting patients who may benefit from
endocrine therapy and is a prognostic marker in metastatic
breast cancer.
Introduction
The development and progression of breast cancer are influ-
enced by steroid hormones, particularly estrogen, via their
interaction with specific target receptors. Endocrine therapy
has become the most important treatment option for women
with estrogen receptor (ER)-positive breast cancer. Neverthe-
less, many breast cancer patients with tumors expressing high
levels of ER are unresponsive to endocrine therapy, and all
patients with advanced disease eventually develop resistance
to the therapy. The potential mechanisms behind either this
intrinsic or acquired endocrine resistance involve ER-coregu-
latory proteins and crosstalk between the ER pathway and
other growth factor signaling networks [1,2]. An understand-
ing of the molecular mechanisms that modulate the activity of
the estrogen signaling network has enabled new ways of over-
coming endocrine resistance to be developed.
ER-α  is phosphorylated on multiple amino acid residues [3].
Serines 104, 106, 118, and 167 are all located within the acti-
vation function (AF)1 region of ER-α , and their phosphoryla-
tion provides the important mechanism that regulates AF1
activity [4,5]. In response to estradiol binding, human ER-α  is
AF = action function; DMEM = Dulbecco's modified essential medium; E2 = 17β -estradiol; EGF = epidermal growth factor; ER = estrogen receptor; 
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phosphorylated mainly on Ser118 and to a lesser extent on
Ser104 and Ser106 [4]. Although some authors have also
reported that Ser167 is a major estradiol-induced phosphor-
ylation site [5,6], this response to estradiol has not been uni-
versally observed [4,7]. Interestingly, in response to the
activation of the mitogen-activated protein kinase (MAPK)
pathway, phosphorylation occurs on Ser118 and Ser167
[8,9]. However, the role of phosphorylation of Ser118 and
Ser167 of ER-α  in human breast cancer has not been
investigated.
ER-β  and its splicing isoforms are widely expressed in both
normal and malignant breast tissue [10]. Although several
groups have reported results regarding the possible function
of ER-β , and its potential as a prognostic or predictive factor
in breast cancer, the data remain inconclusive and are often
contradictory [11,12]. ER-β cx (also called ER-β 2), a splice var-
iant of ER-β , is considered to be a dominant repressor of ER-
α ; it is identical to ER-β 1 (wild-type ER-β ) except that the last
exon, 8, is replaced by 26 amino acid residues [13]. The role
of ER-β  and its isoforms, especially with respect to the
response of breast cancer to endocrine therapy, has also not
been elucidated.
Progesterone receptors (PRs) occur as two isoforms, PRA
and PRB, transcribed from two distinct promoters on a single
gene. PRA, but not PRB, lacks the 164 amino acid N-terminal
residues that contain AF3, and this is the cause of their func-
tional differences [14]. In the mammary gland, the overexpres-
sion of PRA relative to PRB results in extensive epithelial cell
hyperplasia, excessive ductal branching, and a disorganized
basement membrane, all features associated with neoplasia
[15]. In contrast, the overexpression of PRB leads to prema-
ture arrest of ductal growth and inadequate lobuloalveolar dif-
ferentiation [16]. However, little is known about the unique
roles of the two PR isoforms in breast cancer.
In this study, we focused on the expression and phosphoryla-
tion of the hormone receptors themselves and, using immuno-
histochemistry (IHC), examined the phosphorylation of ER-α
Ser118 and Ser167 and the expression of ER-α , ER-β 1, ER-
β cx/β 2, PR, PRA, and PRB in primary breast tumor specimens
from 75 patients with metastatic breast cancer who received
first-line treatment with endocrine therapy on relapse. Our
results show that patients with primary breast tumors in which
there is either high phosphorylation of ER-α  Ser167 or high
expression of ER-α , PR, PRA, or PRB significantly responded
to endocrine therapy and had a better survival after relapse.
Materials and methods
Cell culture and transfections
COS-7 cells (ATCC American Type Culture Collection, Man-
assas, VA, USA) were grown in DMEM containing 10% fetal
calf serum, 2 mM L-glutamine, and penicillin–streptomycin (50
IU/ml and 50 mg/ml, respectively) at 37°C with 5% CO2 as
described previously [17]. T47D cells (ATCC) were grown in
RPMI-1640 supplemented with 10% fetal calf serum, 2 mM L-
glutamine, and penicillin–streptomycin (50 IU/ml and 50 mg/
ml, respectively), at 37°C with 5% CO2. Six microliters of
FuGENE6 transfection reagent (Roche Molecular Biochemi-
cals, Indianapolis, IN, USA), 3 µg of an expression vector for
human ER-α  cDNA (pSG5/puromycine hERα , full length,
kindly provided by Pierre Chambon, Strasbourg, France) were
used for transfection into COS-7 cells as described previously
[18]. After transfection, cells were starved in serum-free
DMEM without phenol red for 20 hours.
Immunoblotting
Cells were treated in the absence or presence of 17β -estra-
diol (E2) (10 nM, Sigma-Aldrich Co, St Louis, MO, USA) and/
or epidermal growth factor (EGF) (100 ng/ml, human recom-
binant EGF, Sigma-Aldrich) for 30 min, pelleted by centrifuga-
tion and solubilized in lysis buffer containing 10 mM Tris-HCl,
pH 7.6, 5 mM EDTA, 50 mM NaCl, 30 mM sodium pyrophos-
phate, 50 mM sodium fluoride, 1 mM sodium orthovanadate,
1% Triton X-100, 1 mM phenylmethylsulfonylfluoride (PMSF),
5 µg/ml aprotinin, 1 µg/ml pepstatin A, and 2 µg/ml leupeptin,
as described previously [19]. Equal amounts of total protein
from whole-cell lysates were prepared and used for SDS–
PAGE. Immunoblotting was performed as described previ-
ously [18] using polyvinylidene difluoride (PVDF) membranes
(Invitrogen, Carlsbad, CA, USA; Catalogue no. LC2002), and
polyclonal antibody against ER-α  (H-184, Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) (1:200 dilution), polyclonal rab-
bit antiphospho-ER-α  (Ser118) antibody (Cell Signaling
Technology, Beverly, MA, USA) (1:500 dilution), polyclonal
rabbit antiphospho-ER-α  (Ser167) antibody (Cell Signaling)
(1:500 dilution) as primary antibodies and horseradish-peroxi-
dase-conjugated goat antibodies to rabbit IgG as secondary
antibodies in conjunction with enhanced chemiluminescence
substrate mixture (SuperSignal WestPico Chemiluminescent
Substrate, Pierce, Rockford, IL, USA) in accordance with the
manufacturer's instructions. Phospho-ER-α  Ser118 antibody
detects ER-α  only when the receptor is phosphorylated at
Ser118, and not at Ser106 or Ser167; and phospho-ER-α
Ser167 antibody detects ER-α  only when the receptor is
phosphorylated at Ser167, and not at Ser106 or Ser118, by
immunoblotting, as described by Chen and colleagues [20].
Generation of specific antibodies for ER-β  proteins
To detect specific ER-β 1 and ER-β cx/β 2 proteins, rabbit poly-
clonal antibodies were generated against synthesized pep-
tides of the C-terminal region of ER-β 1
(CSPAEDSKSKEGSQNPQSQ) and ER-β cx/β 2
(MKMETLLPEATMEQ), in accordance with the method of
Ogawa and colleagues [13] and purified on affinity columns
bound with each synthetic peptide as described previously
[17]. To confirm the specificity of these polyclonal antibodies,
immunoblot analysis was performed using COS-7 cells trans-
fected with either expression plasmid encoding ER-β 1 or ER-Available online http://breast-cancer-research.com/content/7/5/R753
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β cx/β 2 (kindly donated by Masami Muramatsu, Saitama,
Japan) as previously described [18]. Immunoblotting with spe-
cific anti-ER-β  antibodies showed that the polyclonal antibody
for ER-β 1 detected a specific band at 60 kDa only in the
lysates of COS-7 cells transfected with an ER-β 1 expression
plasmid, and not in those transfected with an ER-β cx/β 2
expression plasmid, as described previously by Ogawa and
colleagues [13]. Conversely, the polyclonal antibody for ER-
β cx/β 2 detected a specific band at 55 and 51 kDa only in the
lysates of COS-7 cells transfected with an ER-β cx/β 2 expres-
sion plasmid, and not in those transfected with an ER-β 1
expression plasmid, as described previously by Ogawa and
colleagues [13].
Patients and breast cancer tissues
Breast tumor specimens from 75 women with metastatic
breast cancer who were treated at Nagoya City University
Hospital between 1982 and 2002 were included in this study
(Table 1). The study protocol was approved by the institutional
review board and conformed with the guidelines of the 1975
Declaration of Helsinki. All patients had undergone surgical
treatment for primary breast cancer (either mastectomy or
lumpectomy) and all primary tumors were ER+ or PR+. After
surgery, five patients (6.7%) received no additional therapy. Of
the remaining 71 patients, 32 (42.7%) received systemic adju-
vant therapy consisting of endocrine therapy (tamoxifen)
alone, two (2.7%) received chemotherapy alone, and 36
(48%) received combined endocrine therapy and chemother-
apy. Patients who were positive for axillary lymph nodes
received either oral administration of 5-fluorouracil derivatives
for 2 years or a combination of cyclophosphamide, methotrex-
ate, and fluorouracil (CMF). Patients were observed for dis-
ease recurrence at least once every six months for the first 5
years after the surgery and once every year thereafter.
First-line endocrine therapy for metastatic breast cancer 
and response criteria
When the patients relapsed and were diagnosed with meta-
static breast cancer, they started endocrine therapy (Table 1).
Patients were assessed monthly for clinical response, which
was defined according to World Health Organization criteria
as complete response, partial response, no change, or pro-
gressive disease. The presence of progressive disease indi-
cated treatment failure; all other clinical responses were
considered to show efficacy of treatment.
Immunohistochemical analysis
One 4-µm section of each submitted paraffin block was
stained first with hematoxylin and eosin to verify that an ade-
quate number of invasive carcinoma cells were present and
that the fixation quality was adequate for immunohistochemical
(IHC) analysis. Serial sections (4 µm) were prepared from
selected blocks and float-mounted on adhesive-coated glass
slides, for ER-α , ER-β , and PR staining as described previ-
ously [21]. Primary antibodies included monoclonal mouse
Table 1
Clinicopathological characteristics of patients with metastatic 
breast cancer, their primary tumors, and treatment
Characteristic Number of patients
Total number of patients 75
Age at diagnosis (years)
≤ 50 35
>50 40
Range 29 to 77
Tumor size (cm)
<2.0 20
≥ 2.0 55
Number of positive lymph nodes
02 1
1–3 21
>3 33
Histological grade
11 2
24 3
32 0
HER2
Negative 63
Positive 12
Adjuvant therapy
None 5
Endocrine therapy 32
Chemotherapy 2
Combined 36
Disease-free interval (months)
Mean ± standard deviation 39.9 ± 26.4
Median 38
Range 1 to 123
First-line endocrine therapy
Tamoxifen 56
Aromatase inhibitors 11
LH-RH agonist 3
LH-RH agonist + tamoxifen 4
Fulvestrant 1
LH-RH agonist, luteinizing hormone–releasing hormone agonist.Breast Cancer Research    Vol 7 No 5    Yamashita et al.
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antihuman ER-α  antibody (1D5, DAKO, Glostrup, Denmark) at
1:100 dilution for ER-α ; polyclonal rabbit antiphospho-ER-α
(Ser118) antibody (Cell Signaling) at 1:25 dilution for phos-
phorylated ER-α  Ser118; polyclonal rabbit antiphospho-ER-α
(Ser167) antibody (Cell Signaling) at 1:50 dilution for phos-
phorylated ER-α  Ser167; polyclonal rabbit anti-ER-β 1 anti-
body at 1:10000 dilution for ER-β 1; polyclonal rabbit anti-ER-
β cx/β 2 antibody at 1:2000 dilution for ER-β cx/β 2; monoclonal
mouse antihuman PR antibody (636, DAKO) at 1:100 dilution
for PR; monoclonal mouse antihuman PR antibody (Ab-7, Neo
Markers, Fremont, CA) at 1:100 dilution for PRA; and mono-
clonal mouse antihuman PR antibody (Ab-2, Neo Markers) at
1:100 dilution for PRB. With respect to the PRA and PRB anti-
bodies, it has been reported that whereas AB-7 can recognize
high-PRA and low-PRB forms, this antibody recognizes PRA
only in 10% formalin-fixed and paraffin-embedded tissue sec-
tions, and AB-2 recognizes exclusively PRB in these same
media [22]. The DAKO Envision system (DAKO EnVision
labelled polymer, peroxidase) was used as the detection sys-
tem as described previously [21]. HER2 immunostaining was
done and evaluated using a method similar to the HercepTest
(DAKO) [21].
Immunohistochemical scoring
Immunostained slides were scored after the entire slide had
been evaluated by light microscopy. The expression and phos-
phorylation of hormone receptors were scored by assigning
proportion and intensity scores, in accorance with the proce-
dure of Allred and colleagues [23]. In brief, a proportion score
represented the estimated proportion of tumor cells staining
positive, as follows: 0 (none); 1 (<1/100); 2 (1/100 to 1/10);
3 (>1/10 to 1/3); 4 (>1/3 to 2/3); and 5 (>2/3). Any brown
nuclear staining in invasive breast epithelium counted towards
the proportion score. An intensity score represented the aver-
age intensity of the positive cells, as follows: 0 (none); 1
(weak); 2 (intermediate); and 3 (strong). The proportion and
intensity scores were then added to obtain a total score, which
could range from 0 to 8.
Statistical analysis
The Mann–Whitney U  test or the Kruskal–Wallis test was
used to compare the IHC scores of hormone receptors with
clinicopathological characteristics. The Mann–Whitney U test
and the unpaired t-test were used to compare the IHC scores
of hormone receptors with response to endocrine therapy. The
Spearman rank correlation test was used to study relations
between expression and phosphorylation of hormone recep-
tors and disease-free interval. To examine the change of
expression and phosphorylation status between the primary
and recurrent tumors, the one-sample Wilcoxon signed rank
test was used. Estimation of overall survival was performed
using the Kaplan–Meier method, and differences between sur-
vival curves were assessed with the log-rank test. Cox's pro-
portional hazards model was used for univariate and
multivariate analyses of prognostic values.
Results
Phosphorylation of ER-α  Ser118 and ER-α  Ser167 is 
induced in response to EGF
To test the ability of site-specific antiphosphoserine antibodies
for ER-α  Ser118 and ER-α  Ser167, we examined the phos-
phorylation status of these two serines in transfected COS-7
cells by immunoblotting. Cells were grown in serum- and
estrogen-deprived conditions and treated with vehicle
(medium) (Fig. 1a, lane 1), E2 (lane 2), EGF (lane 3), or E2 and
EGF (lane 4). Immunoblotting of replicate samples with
antiphohphoserine antibodies showed that ER-α  was constitu-
tively phosphorylated on Ser118 (Fig. 1a, lane 1, top panel),
but not on Ser167 (Fig. 1a, lane 1, second panel). ER-α
became inducibly phosphorylated on both residues Ser118
Figure 1
Immunoblot analysis of phosphorylated estrogen receptor (ER)-α   Ser118 and ER-α  Ser167 Immunoblot analysis of phosphorylated estrogen receptor (ER)-α  
Ser118 and ER-α  Ser167. (a) Transfected COS-7 cells were grown in 
serum- and estrogen-deprived conditions and treated with vehicle 
(medium) (lane 1), 17β -estradiol (E2) (lane 2), epidermal growth factor 
(EGF) (lane 3), or E2 and EGF (lane 4) for 30 min. Equal amounts of 
total protein from whole cell lysates were blotted for either anti-ER-α -
phosphoserine (α -pS118 and α -pS167) and anti-ER-α  (α -ER-α ) anti-
bodies. (b) T47D cells were grown in serum- and estrogen-deprived 
conditions and treated with vehicle (medium) (lane 1), 17β -estradiol 
(E2) for 10 min (lane 2) and 30 min (lane 3), EGF for 10 min (lane 4) 
and 30 min (lane 5), or E2 and EGF for 10 min (lane 6) and 30 min (lane 
7). Equal amounts of total protein from whole cell lysates were blotted 
for either anti-ER-α -phosphoserine (α -pS118 and α -pS167) and anti-
ER-α  (α -ER-α ) antibodies.Available online http://breast-cancer-research.com/content/7/5/R753
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and Ser167 in response to EGF (Fig. 1a, lanes 3 and 4, top
and second panels). On the other hand, phosphorylation of
Ser118 and Ser167 was not affected with E2 treatment in our
analysis (Fig. 1a, lane 1 vs 2, lane 3 vs 4, top and second pan-
els). Expression of ER-α  was observed equally in each condi-
tion (Fig. 1a, bottom panel).
To further validate the ability of site-specific antibodies for
phospho-ER-α  Ser118 and Ser167 in ER+ and PR+ breast
cancer cells, phosphorylation of ER-α  Ser118 and Ser167
was analyzed in T47D cells. Cells were grown in serum- and
estrogen-deprived conditions and treated with vehicle
(medium) (Fig. 1b, lane 1), E2 for 10 min (lane 2) and 30 min
(lane 3), EGF for 10 min (lane 4) and 30 min (lane 5), or E2 and
EGF for 10 min (lane 6) and 30 min (lane 7). ER-α  was induc-
ibly phosphorylated on Ser167 in response to EGF (Fig. 1b,
lanes 1, 4, 5, 6, and 7, second panel). Phosphorylation of
Ser167 was increased with EGF treatment for 30 min com-
pared with that for 10 min (lane 5 vs 4, lane 7 vs 6). On the
other hand, ER-α  was not phosphorylated on Ser167 in
response to E2 (Fig. 1b, lanes 2 and 3, second panel). In addi-
tion, ER-α  was not phosphorylated on Ser118 in response to
either E2 or EGF (Fig. 1b, lanes 2 to 7, top panel) in T47D cells.
Expression of ER-α  was observed equally under both condi-
tions (Fig. 1b, bottom panel). We concluded from immunoblot-
ting that, in response to EGF in COS-7 and T47D cells, ER-α
Ser167 was inducibly rather than constitutively phosphor-
ylated, and that the phosphorylation of ER-α  Ser118 was con-
stitutive and further induced by EGF in COS-7 cells, but that
Ser118 phosphorylation was not observed after the stimula-
tion of T47D cells by either E2 or EGF.
Immunohistochemical staining for phosphorylation of 
ER-α  Ser118 and ER-α  Ser167, and expression of ER-β  1, 
ER-β cx/β 2, PRA, and PRB in human breast cancer
To investigate the phosphorylation of ER-α  Ser118 and ER-α
Ser167 in human breast cancer specimens, IHC analysis was
performed using the same site-specific antiphosphoserine
antibodies served in the immunoblotting. IHC for phosphor-
ylated ER-α  Ser118 (Fig. 2a) and ER-α  Ser167 (Fig. 2d)
showed presence of nuclear staining in some but not all cells
of normal breast epithelium (Fig. 2). Cancer cell nuclei of inva-
sive carcinoma tissues were positively stained with specific
antibodies for phosphorylated ER-α  Ser118 (Fig. 2c) and ER-
α  Ser167 (Fig. 2f). Specific detection of expression of ER-β 1
(Fig. 3a), ER-β cx/β 2 (Fig. 3b), PRA (Fig. 3c), and PRB (Fig.
3d) showed positive nuclear staining in carcinoma cells.
Figure 2
Representative immunohistochemical staining of estrogen receptor (ER)-α  Ser118, and ER-α  Ser167 in normal breast epithelium and invasive duc- tal carcinoma Representative immunohistochemical staining of estrogen receptor (ER)-α  Ser118, and ER-α  Ser167 in normal breast epithelium and invasive duc-
tal carcinoma. Phosphorylation of ER-α  Ser118 in (a) normal breast epithelium and (b,c) invasive ductal carcinoma: negative (b) and positive (c) 
nuclear staining was observed in carcinoma cells. Phosphorylation of ER-α  Ser167 in (d) normal breast epithelium and (e,f) invasive ductal carci-
noma: negative (e) and positive (f) nuclear staining was observed in carcinoma cells (magnification, 400×).Breast Cancer Research    Vol 7 No 5    Yamashita et al.
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Correlation between expression and phosphorylation of 
ER-α , ER-β , and PR and clinicopathological factors in 
primary breast tumors
We examined the phosphorylation of ER-α  Ser118 and
Ser167, and expression of ER-α , ER-β 1, ER-β cx/β 2, PR, PRA,
and PRB in 75 primary invasive breast carcinomas by IHC. The
IHC scores for ER-α , ER-β , and PR were compared among
patient subgroups, according to clinicopathological factors.
Phosphorylation of ER-α  Ser118, but not of ER-α  Ser167,
was positively correlated with expression levels of HER2 (P =
0.038), whereas expression of ER-α  (1D5) tended to be
inversely correlated with HER2 overexpression. PR (636)
expression was significantly associated with age (P  =
0.0018). There was no difference between the expression and
phosphorylation of hormone receptors and other clinicopatho-
logical factors.
Correlation between expression and phosphorylation of 
ER-α , ER-β , and PR in primary breast tumors
Links between the IHC scores for the expression and phos-
phorylation of hormone receptors were analyzed using the
Spearman's rank correlation test (Table 2). Phosphorylation of
ER-α  Ser118 was strongly and positively associated with
phosphorylation of ER-α  Ser167 (P  < 0.0001) and with
expression of ER-β 1 (P < 0.0001), ER-β cx/β 2 (P < 0.0001),
and PRA (P < 0.0001). Phosphorylation of ER-α  Ser167 was
also positively correlated with expression of ER-β 1 (P  =
0.0003), ER-β cx/β 2 (P < 0.0001), and PRA (P = 0.0007),
whereas no association was found between phosphorylation
of ER-α  Ser118/Ser167 and expression of ER-α  (1D5). A sig-
nificant correlation was observed between expression levels of
ER-β 1 and ER-β cx/β 2 (P < 0.0001). Expression of ER-β cx/β 2,
but not ER-β 1, was positively correlated with expression of
PRA (P  = 0.0011) and PRB (P  = 0.0052). Strong
associations were found between expression of PR (636),
PRA, and PRB (P < 0.0001, respectively). Expression of ER-
α  (1D5) was significantly correlated with expression of PR
(636) (P = 0.0001) and PRA (P = 0.028), but not with PRB.
Phosphorylation of ER-α  Ser167, but not Ser118, and 
expression of PRA and PRB in primary breast tumors are 
predictive of response to endocrine therapy in 
metastatic breast cancer
At relapse, all patients received endocrine therapy as first-line
treatment for metastatic breast cancer; 35 (46.7%) patients
responded. We analyzed whether the expression and phos-
Figure 3
Representative immunohistochemical staining of estrogen receptor (ER)-β 1 (a,b), ER-β cx/β 2 (c,d), progesterone receptor (PR)A (e,f), and PRB  (g,h) in invasive ductal carcinoma Representative immunohistochemical staining of estrogen receptor (ER)-β 1 (a,b), ER-β cx/β 2 (c,d), progesterone receptor (PR)A (e,f), and PRB 
(g,h) in invasive ductal carcinoma. Negative (a,c,e,g) and positive (b,d,f,h) nuclear staining was observed in these cells.Available online http://breast-cancer-research.com/content/7/5/R753
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phorylation levels of hormone receptors in the primary breast
tumors affected the response to endocrine therapy when
given in this circumstance (Table 3). Patients with primary
breast tumors that had high phosphorylation of ER-α  Ser167,
or high expression of ER-α  (1D5), PR (636), PRA, or PRB, sig-
nificantly responded to endocrine therapy (Mann-Whitney U
test, P = 0.033, P = 0.0045, P = 0.0008, P = 0.0001, and P
= 0.013, respectively). Interestingly, these patients with pri-
mary breast tumors with high phosphorylation or expression of
the above factors also had a longer disease-free interval (com-
pare Tables 3 and 4). In contrast, phosphorylation of ER-α
Ser118 or expression of ER-β 1 or ER-β cx/β 2 did not affect
response to endocrine therapy. In the subgroup with HER2
overexpression (n  = 12), phosphorylation of ER-α  Ser118
(IHC scores ≥ 3) was observed in all cases except one,
whereas phosphorylation of ER-α  Ser167 (IHC scores ≥ 3)
was found in only six. Furthermore, endocrine therapy was
Table 2
Correlations between immunohistochemistry scores for expression and phosphorylation of hormone receptors in primary breast 
tumors
Receptor ER-α  (1D5) ER-α  Ser118 ER-α  Ser167 ER-β 1E R - β cx/β 2 PR (636) PRA
ER-α  Ser118 +0.224a
0.055b
ER-α  Ser167 +0.140 +0.556
0.23 <0.0001*
ER-β 1 +0.039 +0.589 +0.417
0.74 <0.0001* 0.0003*
ER-β cx/β 2 +0.009 +0.640 +0.518 +0.693
0.94 <0.0001* <0.0001* <0.0001*
PR (636) +0.446 +0.032 +0.011 +0.004 -0.015
0.0001* 0.78 0.92 0.97 0.90
PRA +0.256 +0.463 +0.394 +0.203 +0.378 +0.500
0.028* <0.0001* 0.0007* 0.081 0.0011* <0.0001*
PRB +0.187 +0.211 +0.149 +0.206 +0.325 +0.553 +0.526
0.11 0.070 0.20 0.077 0.0052* <0.0001* <0.0001*
aSpearman correlation coefficient; bP, Spearman rank correlation test. * P <0.05.
ER, estrogen receptor; PR(A,B), progresterone receptor (A,B).
Table 3
Correlation between immunohistochemistry scores for hormone receptors and response to endocrine therapy in breast cancer
Receptor Responders (n = 35)a Nonresponders (n = 40)a Pb Pc
ER-α  (1D5) 5.8 ± 2.3 (7; 0–8) 4.1 ± 2.9 (5; 0–8) 0.0045* 0.0046*
ER-α  Ser118 4.3 ± 2.6 (5; 0–8) 4.2 ± 2.4 (4; 0–8) 0.90 0.96
ER-α  Ser167 2.5 ± 2.0 (2; 0–6) 1.6 ± 1.7 (2; 0–5) 0.033* 0.025*
ER-β 1 4.2 ± 2.2 (4; 0–8) 4.5 ± 2.3 (5; 0–8) 0.43 0.57
ER-β cx/β 2 3.1 ± 2.4 (3; 0–8) 3.0 ± 2.5 (2; 0–8) 0.72 0.80
PR (636) 5.5 ± 2.5 (6; 0–8) 3.6 ± 2.7 (4; 0–8) 0.0008* 0.0014*
PRA 4.6 ± 2.0 (5; 0–8) 2.4 ± 2.5 (2; 0–8) 0.0001* <0.0001*
PRB 4.0 ± 2.1 (4; 0–8) 2.7 ± 2.4 (3; 0–8) 0.013* 0.015*
aValues are means ± standard deviations (medians; ranges). bMann–Whitney U test. cUnpaired t-test. *P <0.05. ER, estrogen receptor; PR(A,B), 
progresterone receptor (A,B).Breast Cancer Research    Vol 7 No 5    Yamashita et al.
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effective in only three (25%) patients in the HER2-positive
group (data not shown).
Correlation between expression and phosphorylation of 
ER-α , ER-β , and PR in primary breast tumors and 
disease-free interval
We then examined whether the expression and phosphoryla-
tion levels of hormone receptors in primary breast tumors
affected disease-free interval in relapsing breast cancer
patients. Spearman correlation coefficients between the IHC
scores of ER-α , ER-β , and PR and disease-free interval are
shown in Table 4. The time to relapse after primary surgery
was significantly longer in patients with primary breast tumors
with high phosphorylation levels of ER-α  Ser167 or with high
expression levels of ER-α  (1D5), PR (636), PRA, or PRB (P =
0.0076, P = 0.035, P = 0.018, P = 0.0061, and P = 0.023,
respectively). On the other hand, no significant relation was
observed between either phosphorylation of ER-α  Ser118 or
expression of ER-β 1 or ER-β cx/β 2 and disease-free interval.
Comparison of IHC scores of ER-α , ER-β , and PR in 
primary and secondary tumors
Biopsy specimens were obtained from the secondary tumors
of 10 patients after relapse. Six were local skin or subcutane-
ous tumors, two were axillar or supraclavicular lymph nodes,
and two were distant (lung) tumors. Phosphorylation of ER-α
Ser118 was much higher in secondary than in primary tumors
(P = 0.0098) (Table 5). There was also a tendency for phos-
phorylation of ER-α  Ser167 to increase in secondary tumors,
although this did not reach significance. Furthermore, the IHC
scores of ER-β 1, ER-β cx/β 2, PRA, and PRB were all signifi-
cantly higher in secondary than in primary tumors (P = 0.041,
P = 0.049, P = 0.018, and P = 0.027, respectively), while
expression levels of ER-α  (1D5) and PR (636) were lower in
secondary than in primary tumors.
Patients with high phosphorylation of ER-α  Ser167 and 
high expression of PRA and PRB in primary breast 
tumors had a significantly longer survival after relapse
Finally, we analyzed whether the expression and phosphoryla-
tion levels of hormone receptors in the primary breast tumors
Table 4
Correlation between immunohistochemistry scores for hormone receptors and disease-free interval
Receptor Spearman correlation coefficient Spearman rank correlation test (P)
ER-α  (1D5) +0.246 0.035*
ER-α  Ser118 +0.083 0.47
ER-α  Ser167 +0.310 0.0076*
ER-β 1 +0.039 0.74
ER-β cx/β 2 +0.101 0.39
PR (636) +0.276 0.018*
PRA +0.319 0.0061*
PRB +0.263 0.023*
*P <0.05. ER, estrogen receptor; PR, progresterone receptor.
Table 5
Comparison of immunohistochemistry scores for hormone receptors in primary and secondary tumors
Receptor Primary tumorsa Secondary tumorsa P
ER-α  (1D5) 4.9 ± 2.7 3.1 ± 3.2 0.049*
ER-α  Ser118 4.9 ± 2.8 7.3 ± 1.6 0.0098*
ER-α  Ser167 3.7 ± 1.6 5.5 ± 2.2 0.11
ER-β 1 5.5 ± 2.2 7.0 ± 2.0 0.041*
ER-β cx/β 2 4.1 ± 2.6 6.1 ± 2.6 0.049*
PR (636) 4.1 ± 3.2 2.9 ± 3.5 0.057
PRA 3.5 ± 2.6 6.1 ± 2.6 0.018*
PRB 3.7 ± 2.4 5.7 ± 2.6 0.027*
aMean ± SD. n = 10. *P <0.05. ER, estrogen receptor; PR(A,B), progresterone receptor (A,B).Available online http://breast-cancer-research.com/content/7/5/R753
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Figure 4
Postrelapse survival of patients analyzed according to expression of (a) estrogen receptor (ER)-α , (b) phosphorylation of ER-α  Ser167, and (c)  expression of progesterone receptor (PR), (d) PRA, and (e) PRB Postrelapse survival of patients analyzed according to expression of (a) estrogen receptor (ER)-α , (b) phosphorylation of ER-α  Ser167, and (c) 
expression of progesterone receptor (PR), (d) PRA, and (e) PRB. Higher levels of expression or phosphorylation of these factors were associated 
with a better survival.
Table 6
Univariate and multivariate analysis of factors predicting postrelapse survival
Univariate Multivariate
Factor P RR 95% CI P RR 95% CI
Age 0.67 0.882 0.494–1.576
Tumor size 0.21 1.483 0.797–2.759
Lymph node status 0.40 0.746 0.376–1.479
Histological grade 0.20 0.542 0.213–1.382
HER2 0.0033* 0.340 0.166–0.699
ER-α  (1D5) 0.0009* 2.924 1.550–5.515 0.0076* 2.465 1.271–4.781
ER-α  Ser118 0.36 1.308 0.732–2.340
ER-α  Ser167 0.035* 1.890 1.045–3.420 0.19 1.536 0.841–2.900
ER-β 1 0.37 1.355 0.697–2.635
ER-β cx/β 2 0.10 1.627 0.905–2.926
PR (636) 0.0012* 2.796 1.498–5.220
PRA 0.03* 2.182 1.202–3.960
PRB 0.013* 2.157 1.177–3.951 0.24 1.499 0.763–2.945
CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor; RR, relative risk. *P < 0.05.Breast Cancer Research    Vol 7 No 5    Yamashita et al.
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affected the survival after relapse. The median follow-up period
was 77 months (range, 4 to 234 months). High expression of
ER-α  (1D5) (IHC score ≥ 3) significantly increased pos-
trelapse survival (P = 0.0005) (Fig. 4a). Patients with high
phosphorylation of ER-α  Ser167 (IHC score ≥ 2) had a
significant longer postrelapse survival (P = 0.03) (Fig. 4b).
Similarly, high expression of PR (IHC score ≥ 3), PRA (IHC
score ≥ 4), and PRB (IHC score ≥ 3) significantly increased
postrelapse survival (P = 0.0008, P = 0.009, and P = 0.01,
respectively) (Fig. 4c,d,e). Univariate analysis (Table 6)
revealed significant associations between postrelapse survival
and phosphorylation of ER-α  Ser167 (P = 0,035), as well as
expression of ER-α  (1D5) (P  = 0,0009), PR (636) (P  =
0,0012), PRA (P = 0,03), and PRB (P = 0,013). On the other
hand, phosphorylation of ER-α  Ser118 and expression of ER-
β 1 and ER-β cx/β 2 did not affect postrelapse survival. The sta-
tus of phosphorylation of ER-α  Ser167, expression of ER-α
(1D5), and PRB were selected for the multivariate analysis
because these three factors were significant in the univariate
analysis and no significant association was found between
IHC scores of these factors. Patients with primary tumors with
high expression of ER-α  (1D5) had significantly increased
overall survival (P = 0.0076), whereas phosphorylation of ER-
α  Ser167 or expression of PRB were insignificant in the multi-
variate analysis (Table 5).
Discussion
Using IHC techniques, we investigated the phosphorylation of
ER-α  Ser118 and ER-α  Ser167, and expression of ER-α , ER-
β 1, ER-β cx/β 2, PR, PRA, and PRB, in primary breast tumor
specimens from 75 patients with metastatic breast cancer
who, on relapse, received endocrine therapy as first-line treat-
ment. Our results indicate that patients with primary breast
tumors with high phosphorylation of ER-α  Ser167, or high
expression of ER-α , PR, PRA, or PRB, significantly respond to
endocrine therapy and had a better survival after relapse.
ER-α  is phosphorylated on multiple amino acid residues [3]. In
general, phosphorylation of serine residues in the AF1 domain
of ER-α  appears to influence the recruitment of coactivators,
resulting in enhanced ER-mediated transcription. In this study,
we measured the phosphorylation of ER-α  Ser118 and
Ser167 as well as the expression of ER-α  in breast cancer by
IHC using site-specific anti-ER-α -phosphoserine antibodies.
Our results showed that phosphorylation of ER-α  Ser118, but
not of ER-α  Ser167, was significantly correlated with expres-
sion levels of HER2. It has been reported that ER-α  was sig-
nificantly phosphorylated on Ser118 in response to either
estradiol binding or the activation of the mitogen-activated pro-
tein kinase (MAPK) pathway, while Ser167 is phosphorylated
by AKT, p90 ribosomal S6 kinase (RSK), and casein kinase II
as well as MAPK [5,7,9,24]. Murphy and colleagues recently
reported that in 45 human breast tumor biopsies phosphoryla-
tion of ER-α  Ser118 correlated with active MAPK [25].
Because MAPK is located downstream of HER2, it is possible
that phosphorylation of ER-α  Ser118 is in part caused by
HER2-MAPK signaling in breast cancer. On the other hand,
phosphorylation of ER-α  Ser167 seems to be led by different
mechanisms.
Our results also showed that while phosphorylation of both
ER-α  Ser118 and Ser167 was strongly and positively
correlated with expression of ER-β  1 and ER-β cx/β 2, there
was no observed association between expression of ER-α  and
ER-β  proteins. Both antibodies for ER-β 1 and ER-β cx/β 2, gen-
erated in this study, were specific against their respective C-
terminal amino acid residues, and positive nuclear staining
was observed in normal breast epithelial cells, noninvasive
ductal carcinoma, and invasive carcinoma. Saunders and col-
leagues also found that there was no quantitative relation
between IHC scores for ER-α  and ER-β  [26]. However, using
IHC, it was reported that ER-β  expression was positively cor-
related with ER-α  and PR [27]. Specific detection of ER-β 1
from other isoforms also indicated a positive correlation
between expression of ER-β 1 and ER-α  [28]. However, no
studies have been reported concerning the relation between
phosphorylation of ER-α  and expression of ER-β  proteins.
In our analysis, ER-α  expression was positively correlated with
PRA but not with PRB. In addition, phosphorylation of both
ER-α  Ser118 and Ser167 was strongly and positively
associated with expression of PRA but not with PRB. This sug-
gests that PRA is preferentially induced following the tran-
scription of ER-α  after the phosphorylation of Ser118 and/or
Ser167. Two previous studies have reported investigations
into the expression of PRA and PRB in breast cancer. The first,
an analysis of 202 PR-positive breast cancers by immunoblot-
ting, showed that while there was no significant difference in
levels of PRA and PRB in most of the PR-positive tumors, nev-
ertheless expression levels of PRA were higher in 59% of
tumors and at least four times as high in 25% [29]. In the sec-
ond study, of 32 PR-positive breast cancers, it was reported
that excess PRB correlated with the absence of HER2,
thereby indicating a good prognosis, whereas excess PRA
correlated with a poorly differentiated phenotype and higher
tumor grade [30]. The normally equal expression of PRA and
PRB is disrupted early in carcinogenesis. PRA is usually the
predominant isoform in tumors of the breast, and it appears,
therefore, that disrupted progesterone signaling may play a
role in the development or progression of these cancers
[14,29,31].
The most important results to come out of this study concern
the correlation between clinical response and the
phosphorylation and expression of the receptors. We identi-
fied that patients with primary breast tumors with high phos-
phorylation of ER-α  Ser167, or high expression of PRA or
PRB, significantly responded to endocrine therapy, whereas
phosphorylation of ER-α  Ser118 and expression of ER-β 1 and
ER-β cx/β 2 did not influence response. Phosphorylation ofAvailable online http://breast-cancer-research.com/content/7/5/R753
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both ER-α  Ser118 and ER-α  Ser167 occurs in response to
either estradiol binding or activation of growth factor signaling
pathways. It is well established that peptide growth factor sig-
naling pathways can activate ER-α , in the absence of its lig-
and, through phosphorylation of ER-α  by MAPK [8,32]. In
addition, the induction of ER-α  by MAPK also enhances ER
signaling and promotes tumor growth in the presence of
estradiol, and such tumors have been shown to be responsive
still to antiestrogen therapy [33]. Furthermore, Clark and col-
leagues reported that, independently of MAPK, p90 ribosomal
S6 kinase 2 (Rsk2) specifically activates ER-α  by phosphor-
ylation of Ser167 and by docking to the hormone-binding
domain of ER-α , and that the antiestrogen 4-hydroxytamoxifen
blocks Rsk2-mediated activation of ER-α  [7]. Since our results
showed that phosphorylation of ER-α  Ser167, but not ER-α
Ser118, was predictive of response to endocrine therapy, they
suggest that, in breast cancer, phosphorylation of ER-α
Ser118 occurs frequently without estradiol, whereas phos-
phorylation of ER-α  Ser167 may occur frequently in response
to estradiol binding.
It has been reported that HER2-induced MAPK and ER-α  acti-
vation leads to tamoxifen resistance [34]. Data from these clin-
ical trials demonstrated that the antiproliferative response to
endocrine therapy was impeded in ER-α -positive/HER2-posi-
tive primary breast cancers [35]. In contrast, a Southwest
Oncology Group study reported that overexpression of HER2
was not associated with tamoxifen unresponsiveness or a
more aggressive phenotype of ER-α -positive metastatic
breast cancer [36]. In our analysis, HER2-positive tumors
showed high phosphorylation levels of ER-α  Ser118 and were
resistant to endocrine therapy.
Finally, our results showed that expression of ER-β 1 and ER-
β cx/β 2 does correlate with response to endocrine therapy. No
significant differences in the expression of ER-β 1, ER-β 2, and
ER-β 5 mRNAs between tamoxifen-sensitive and -resistant
groups, has been reported [37]. Taken together, these data
suggest that the expression of ER-β  proteins is not predictive
of response to endocrine therapy in breast cancer. However,
a significant correlation between a PR-negative phenotype
and the presence of ER-β cx/β 2 in ER-α -rich tumor foci and
expression of ER-β cx/β 2 with low PR expression has been
shown to correlate with a poor response to tamoxifen [38].
In our analysis, the expression of PRA and PRB as well as PR
was strongly predictive of response to endocrine therapy. In
contrast, it has been reported, in a study of T47D human
breast tumor xenografts, that tamoxifen treatment preferentially
inhibited the growth of PRA tumors, whereas PRB tumors
were unaffected [39]. Another study reported that, although
estrogen induced PR expression in all breast cancer cell lines
studied, the expression ratio of PRA/PRB induced by estrogen
was dependent on the cell line, and that these results sug-
gested that the PRA and PRB promoters were differentially
regulated by estrogen in different breast cancer cells [40]. Fur-
ther studies are obviously needed to resolve these apparent
discrepancies and in order to identify the functional impor-
tance of altered PR isoform expression and how this might
affect the response of breast tumors to endocrine therapy.
Conclusion
The present study has shown for the first time that patients
with primary breast tumors with either high phosphorylation of
ER-α  Ser167 or high expression of PRA or PRB respond sig-
nificantly to endocrine therapy and have a better survival after
relapse. Our data suggest that phosphorylation of ER-α
Ser167 is helpful in selecting patients who may benefit from
endocrine therapy and is a prognostic marker in metastatic
breast cancer.
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